Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Frequently asked questions
What sector does Vericel Corporation (VCEL) operate in?
Vericel Corporation belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vericel Corporation (VCEL) current stock price?
As of the latest data, Vericel Corporation stock price is $43.04, with a previous close of $42.53. Vericel Corporation gained $0.51 in the last trading session, representing a 1.2% increase.
What is Vericel Corporation (VCEL) current market capitalization?
Vericel Corporation market cap is approximately 2.20 billion.
What is Vericel Corporation (VCEL) Earnings Per Share (EPS)?
The trailing EPS is $0.49, and the forward EPS is $0.85.
What is Vericel Corporation (VCEL) Price-to-Earnings (P/E) ratio?
Vericel Corporation current P/E ratio is 87.84, with a forward P/E of 50.87.
What is Vericel Corporation (VCEL) EBITDA?
Vericel Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 5.62 million.
Does Vericel Corporation (VCEL) pay dividends?
No. Vericel Corporation does not pay a dividend.
How did Vericel Corporation (VCEL) perform in its most recent earnings report?
In the last report (June 30, 2026), Vericel Corporation posted an EPS surprise of 200% and a revenue surprise of 6.56%.
When is Vericel Corporation (VCEL) next earnings report?
Vericel Corporation is expected to release its next earnings report on September 30, 2026.
What is Vericel Corporation (VCEL) beta (volatility) score?
Vericel Corporation has a beta of 1.048, meaning its volatility is roughly in line with the market.
